Clinical trials: Metastatic Malignant Neoplasm to Brain
Lung Cancer, Nonsmall Cell, Brain Metastases
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.
- Trial name
- NCT04415320
- Testing
- X-396(Ensartinib)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Brain Cancer, Brain Metastases
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that…
- Conditions
- Brain Cancer, Brain Metastases, Melanoma, Lung Cancer
- Trial name
- NCT04899908
- Testing
- Stereotactic Radiation, AGuIX gadolinium-based nanoparticles
- Where
- 2 sites in United States
- Volunteers
- 134 people
- Sponsor
- Brigham and Women's Hospital
Melanoma, Renal Cell Carcinoma
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
The purpose of this study is to collect prospective data for use as a comparator for future subsequent studies attempting to increase the efficacy or reduce the toxicity of gamma knife radiosurgery.
- Conditions
- Melanoma, Renal Cell Carcinoma, Sarcoma, Breast Cancer
- Trial name
- NCT02005614
- Testing
- Gamma Knife Radiosurgery
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Brain Metastases
A Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases
This study will be a non-randomized phase II trial for patients with one to six brain metastases, at least one of which is appropriate for surgical resection.
- Trial name
- NASRS (NCT03368625)
- Testing
- Stereotactic Radiosurgery
- Where
- 2 sites in Canada, Germany
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Brain Metastases, Adult
Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach (POSTPONE)
The management of brain metastases has evolved́ rapidly in recent years. It is estimated that 20% to 40% of cancer patients will develop brain metastases (BM) during the course of their disease.
- Trial name
- POSTPONE (NCT06029140)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Brest
Neoplasm Metastasis
Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)
Whole Brain Radiation Therapy (WBRT) has long been the mainstay of treatment for patients with multiple brain metastases (BM). Meanwhile, Gamma Knife radiosurgery (GKRS) has been increasingly employed in the management of…
- Trial name
- NCT02953717
- Testing
- Gamma Knife radiosurgery, Whole Brain Radiation Therapy
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- Elisabeth-TweeSteden Ziekenhuis
Melanoma With Brain Metastasis
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
This phase II study will evaluate the safety of combining intermediate frequency electric field (TT Field) with immunotherapy in melanoma patients with brain metastasis.
- Trial name
- NCT03903640
- Testing
- Optune, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Phase II Clinical Trial, Ninety-six Histologically Confirmed NSCLC Patients With BM
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients
Background: Whole-brain radiotherapy (WBRT) is the standard treatment for multiple brain metastases (BM), in NSCLC patients who are not candidates for treatment with stereotactic radiation body therapy.
- Conditions
- Phase II Clinical Trial, Ninety-six Histologically Confirmed NSCLC Patients With BM, Randomized 1:1 to Received TN Plus WBR or Only WBR, ICPFS Evaluated by Two Blinded and Independent Radio-oncologist With MRI
- Trial name
- NCT04338867
- Testing
- Whole-brain radiotherapy
- Where
- Mexico
- Volunteers
- 96 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Metastatic Intracranial Malignant Neoplasm, Recurrent Intracranial Neoplasm
18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain
This phase I trial studies the ability and amount of fluciclovine positron emission tomography (PET) imaging needed to recognize tumors that have come back (recurrence) after brain injury from radiation therapy (radionecrosis) in…
- Trial name
- NCT04462419
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography, Fluciclovine F18
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Brain Metastases, Adult, Non Small Cell Lung Cancer
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).
- Conditions
- Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
- Trial name
- SILMET (NCT05689619)
- Testing
- Silibinin
- Where
- 6 sites in Italy
- Volunteers
- 70 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Breast Cancer, Brain Metastasis
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Background: Sometimes breast cancer spreads (metastasizes) to the brain. Researchers want to study new treatments for brain metastases. The drug Temozolomide is approved to treat brain tumors.
- Conditions
- Breast Cancer, Brain Metastasis, Brain Cancer
- Trial name
- NCT03190967
- Testing
- T-DM1, TMZ
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Brain Metastasis, Brain Metastases
Neurocognitive Impact and Dose-Effect Relationship of Hippocampal Avoidance During Whole Brain Radiotherapy Plus Simultaneous Integrated Boost - A Prospective Follow-up Study
For newly-diagnosed patients with brain metastasis, whole brain radiation therapy (WBRT) probably remains a common palliative management even for those with oligometastatic brain disease.
- Trial name
- NCT03223675
- Testing
- hippocampal-sparing WBRT
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Chang Gung Memorial Hospital
Brain Metastases
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After…
- Trial name
- PURSUE (NCT04410367)
- Testing
- 18F fluciclovine
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Blue Earth Diagnostics
Brain and Central Nervous System Tumors, Lymphoma
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Trial name
- NCT00276783
- Testing
- pemetrexed
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Brain Metastases
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain…
- Trial name
- POLARIS (NCT03911869)
- Testing
- encorafenib, binimetinib
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 13 people
- Sponsor
- Pfizer
Lung Cancer, Metastatic Cancer
WBRT & Erlotinib in Advanced NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- TACTIC (NCT00554775)
- Testing
- erlotinib hydrochloride
- Where
- 7 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
- Trial name
- NCT01172912
- Testing
- filgrastim, pegfilgrastim, carboplatin
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Brain Metastases, Brain Metastases, Adult
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of…
- Conditions
- Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
- Trial name
- NCT05559853
- Testing
- CEST-MRF
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited.
- Trial name
- NCT05510466
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Montpellier
Breast Cancer
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
This study aims to investigate the efficacy and safety of utidelone in combination with bevacizumab in the treatment of advanced breast cancer with brain metastases, and thus provides a new systemic treatment strategy for those…
- Trial name
- NCT05357417
- Testing
- utidelone, Bevacizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Henan Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.